Feb. 26, 2013
/PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a patient based U.S. company targeting critical and non-critical ailments through the use of Cannabinoid based formulations, extracts, and products through multiple Phytiva Brand product lines and solutions, strongly encourages like-minded citizens to contact their elected officials in support of safe access to cannabinoids for medical use in conjunction with the "lobby day" efforts of the Americans for Safe Access (ASA) National Medical Cannabis Unity Conference 2013 held in
during the last four days.
Consistent with the findings and discussions at the ASA conference, the Company has already publicly launched two initiatives in this area with its Phytiva Brand European Cannabinoid product line and its Cannabinoid treatment-based facility development agreement with the Maliseet Nation in Eastern Canada.
"As an ASA conference participant, it is clear that the time is now to persuade our regulatory authorities of the proven efficacy of cannabinoid based medicine, products, and treatments. These therapies are already being utilized in the U.S. and around the world in a successful, rigorous, and professional manner. It is in the interest of human healthcare to support these cannabinoid efforts and to place an even greater emphasis on increasing research into the healing properties of cannabinoids," stated
Chad S. Johnson
, Chief Operating Officer and General Counsel of X-Change Corp.
The ASA conference successfully brought together medical cannabinoid patients and supportive medical professionals, scientists, attorneys, policy experts, politicians, and other stakeholders in the medical cannabinoid space to create an environment for enhancing and expanding safe access to life-saving medicines and treatments. With the positively shifting ground around medical cannabinoids, this conference located in the nation's capital, continued to move the U.S. down the rational path of cannabinoid acceptance and use. More information about the mission, agenda and participants of the ASA conference is available at
. With more than eighty percent (80%) of Americans in favor of cannabinoid medicine, the Company is well positioned as a corporation and as a socially responsible entity to continue the Company's leadership in this burgeoning international industry.
About Phytiva Brand Product Lines